<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 29, 1996
NU-TECH BIO-MED, INC.
(Exact Name of Registrant as specified in charter)
<TABLE>
<S> <C> <C>
Delaware 0-11772 25-1411971
- ------------------------------------------------------------------
(State or other jurisdic- (Commission (IRS Employer
tion of incorporation) File Number) Identification No.)
</TABLE>
<TABLE>
<S> <C>
55 Access Road, Warwick, Rhode Island 02886
- ------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code (401) 732-6520
__________________________________________________________________
(Former name or former address, if changed since last report.)
<PAGE> 2
ITEM 5. OTHER EVENTS.
Nu-Tech Bio-Med, Inc. (the "Company") has previously announced that it
had entered into a Letter of Intent on December 6, 1995, with Infotechnology,
Inc. ("Infotech"), Advanced Corporate Services, Inc. ("Advanced"), Questech
Capital, Corp. ("Questech") and American Cytogenetics, Inc. ("ACI") pursuant to
which the Company, subject to the completion of its due diligence and a formal
agreement, would acquire from Infotech, Advanced and Questech all of the Common
and Preferred Shares owned by each of them in ACI representing approximately
53.9% of all of ACI's issued and outstanding shares of Common Stock and
approximately 59.9% of all of ACI's issued and outstanding shares of Preferred
Stock.
As a result of management's ongoing due diligence review of the
business and operations of ACI, management has determined at this time not to
pursue the transaction and has terminated the Letter of Intent and further
negotiations.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
J. Marvin Feigenbaum
Chairman of the Board,
President, Chief Executive
and Chief Financial Officer
Dated: August 29, 1996
2
